- Home
- JL vs ICU Comparison
JL vs ICU Comparison
Compare JL & ICU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JL
- ICU
- Stock Information
- Founded
- JL 1985
- ICU 2018
- Country
- JL Hong Kong
- ICU United States
- Employees
- JL N/A
- ICU N/A
- Industry
- JL
- ICU Biotechnology: Pharmaceutical Preparations
- Sector
- JL
- ICU Health Care
- Exchange
- JL NYSE
- ICU Nasdaq
- Market Cap
- JL 10.0M
- ICU 10.4M
- IPO Year
- JL 2024
- ICU N/A
- Fundamental
- Price
- JL $5.32
- ICU $1.27
- Analyst Decision
- JL
- ICU
- Analyst Count
- JL 0
- ICU 0
- Target Price
- JL N/A
- ICU N/A
- AVG Volume (30 Days)
- JL 23.1K
- ICU 144.4K
- Earning Date
- JL 07-31-2025
- ICU 05-14-2025
- Dividend Yield
- JL N/A
- ICU N/A
- EPS Growth
- JL N/A
- ICU N/A
- EPS
- JL 0.54
- ICU N/A
- Revenue
- JL $32,831,195.00
- ICU $428,000.00
- Revenue This Year
- JL N/A
- ICU $754.07
- Revenue Next Year
- JL N/A
- ICU $100.09
- P/E Ratio
- JL $9.84
- ICU N/A
- Revenue Growth
- JL 7.72
- ICU N/A
- 52 Week Low
- JL $2.33
- ICU $1.11
- 52 Week High
- JL $13.41
- ICU $13.85
- Technical
- Relative Strength Index (RSI)
- JL 70.32
- ICU 51.67
- Support Level
- JL $5.23
- ICU $1.12
- Resistance Level
- JL $5.47
- ICU $1.34
- Average True Range (ATR)
- JL 0.35
- ICU 0.07
- MACD
- JL 0.03
- ICU 0.01
- Stochastic Oscillator
- JL 70.28
- ICU 68.18
About JL J-LONG GROUP LIMITED
J-Long Group Ltd is an established distributor in Hong Kong of reflective and non-reflective garment trims including, among others, heat transfers, fabrics, woven labels and tapes, sewing badges, piping, zipper pullers and drawcords. It also offers a wide range of apparel solution services to cater to its customers' needs for reflective and non-reflective garment trims, ranging from market trend analysis, product design and development and production to quality control.
About ICU SeaStar Medical Holding Corporation
SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses.